Free Newsletter

FEATURES >> 10 largest U.S. patent losses | 15 top blockbuster contenders | Emerging pharma jobs

Related Topics >> FDA | Eli Lilly | Cymbalta

FDA cancels meeting on new Cymbalta use

January 6, 2010 — 10:47am ET | By Tracy Staton

Related Stories

Tools

The FDA has canceled a meeting to review Eli Lilly's antidepressant Cymbalta for a new use against chronic pain, sending the company's stock downward. Report

SHARE
WITH:

More stories about FDA Eli Lilly Cymbalta

Paid Research Reports

Trends in mHealth and Telemedicine
The Global Aesthetic Dermatology Market Outlook
Future Directions in Regenerative Medicine
Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline

More Research Reports >>